secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001104659-22-129610
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics issues $31.82M convertible note to Streeterville; EMA accepts MAA for wet AMD
--------------------------------------------------------------------------------

- Net proceeds ~$30M from $31.82M face convertible note at 9.5%, maturing Jan 1, 2024; repays $11.9M existing note.
- Note convertible at $2.00/share; subject to 4.99% beneficial ownership cap (9.99% if market cap <$25M).
- Company must raise $25M new equity to close; shareholder approval required for issuances above 45.2M share cap.
- EMA validated MAA for ONS-5010 (bevacizumab-vikg) for wet AMD; EU decision expected early 2024.
- U.S. FDA BLA accepted with PDUFA Aug 29, 2023; potential 8-year EU exclusivity, extendable to 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/0001104659-22-129610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/tm2233327d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-129610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer